Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer
Sponsor: Fudan University
Summary
This prospective observational study is to assess the dynamics of circulating tumor DNA (ctDNA) in patients with advanced epithelial ovarian cancer (EOC) undergoing surgery, adjuvant chemotherapy, followed by poly adenosine diphosphate-ribose polymerase (PARP) inhibitors until disease progression or the end of the study. All patients will be closely monitored throughout the course of disease by a tumor-informed bespoke ctDNA assay as well as traditional methods of surveillance, such as CA125 and imaging. This study may provide preliminary evidence for ctDNA-guided treatment decisions in future clinical practice.
Official title: Evaluation of Prognostic and Predictive Values of Bespoke Circulating Tumor DNA Assay for Recurrent and Response Monitoring in Patients With Advanced Epithelial Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
139
Start Date
2021-09-01
Completion Date
2026-12-31
Last Updated
2023-12-28
Healthy Volunteers
No
Conditions
Interventions
ND-EOC or platinum-sensitive rEOC
platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
Locations (1)
Hao Wen
Shanghai, Shanghai Municipality, China